Global molecular landscape of early MASLD progression in human obesity

Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic early on but can progress to irreversible conditions like cirrhosis. Due to limited access to human liver biopsies, systematic and integrative molecular resources remain scarce. In this study, we performed transcriptomic analyses on liver and metabolomic analyses on liver and plasma samples from morbidly obese individuals without liver pathology or at early-stage MASLD. While the plasma metabolomic profile did not fully mirror liver histological features, dual-omics integration of liver samples revealed significantly remodeled lipid and amino acid metabolism pathways. Integrative network analysis uncoupled metabolic remodeling and gene expression as independent features of hepatic steatosis and fibrosis progression, respectively. Notably, GTPases and their regulators emerged as a novel class of genes linked to early liver fibrosis. This study offers a detailed molecular landscape of early MASLD in obesity and highlights potential targets of obesity-linked liver fibrosis.

Authors

Institutions

Publication Details

Journal
eLife
Published
2026-03-23
DOI
https://doi.org/10.7554/elife.109534.3
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Global molecular landscape of early MASLD progression in human obesity

Matthew J. Watt, Sungdong Lee, Gabrielé Sakalauskaite, Ruoyu Wang et al.
eLife
Liver Disease Diagnosis and Treatment
article

Global molecular landscape of early MASLD progression in human obesity

Matthew J. Watt, Sungdong Lee, Gabrielé Sakalauskaite, Ruoyu Wang, Umur Keles, Pradeep Narayanaswamy, Philipp Kaldis, Youngrae Kim, Yi Zhong, Huiyi Tay, William De Nardo, Li Na Zhao, Hyungwon Choi, Guoshou Teo, Rachel Liyu Lim, Mengchao Yan, Ye Xie, Paul R Burton, Sonia Youhanna, Volker M Lauschke, Qing Zhao
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is often asymptomatic early on but can progress to irreversible conditions like cirrhosis. Due to limited access to human liver biopsies, systematic and integrative molecular resources remain scarce. In this study, we performed transcriptomic analyses on liver and metabolomic analyses on liver and plasma samples from morbidly obese individuals without liver pathology or at early-stage MASLD. While the plasma metabolomic profile did not fully mirror liver histological features, dual-omics integration of liver samples revealed significantly remodeled lipid and amino acid metabolism pathways. Integrative network analysis uncoupled metabolic remodeling and gene expression as independent features of hepatic steatosis and fibrosis progression, respectively. Notably, GTPases and their regulators emerged as a novel class of genes linked to early liver fibrosis. This study offers a detailed molecular landscape of early MASLD in obesity and highlights potential targets of obesity-linked liver fibrosis.

eLifeVol. 14
National University of Singapore (SG), Lund University (SE), The Alfred Hospital (AU), Karolinska Institutet (SE), First Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE), Monash University (AU), Yandex (Russia) (RU), RMIT University (AU)
Openalex Percentile: Top 14%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.